RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:319322

Mucinous tubular and spindle cell renal carcinoma

high confidenceDisorder

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

101

51.2th percentile

Trials

0

Interventional, condition-specific

Researchers

556

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Mucinous tubular and spindle cell renal carcinoma is a rare subtype of renal cell carcinoma characterized, histologically, by tubular architecture and sheets of spindle cells embedded in a mucinous/myxoid stroma and, macroscopically, by a solid, generally well-circumscribed, partially encapsulated tumor of variable size, with a homogenously colored, bulging cut surface, occassionally containing areas of hemorrhage or necrosis, usually located in the cortex. Patients can present abdominal/flank pain, adbominal mass and/or hematuria, however most are asymptomatic and tumor is discovered incidentally. Indolent behavior is frequent and association with nephrolithiasis and end-stage kidney disease has been noted.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

carcinoma, renal, tubular, malignant · mucinous tubular and spindle cell carcinoma of the kidney · mucinous tubular and spindle cell renal carcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    101 matched papers (44 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 48 for broader category renal carcinoma

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

101

101 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

101 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

44 in the last 10 years · high confidence · 51.2th percentile (publications denominator)

Phrase hits: 101 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

556

Distinct author names in 101 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Nagashima Y4 papers · 2021

    Department of Surgical Pathology, Tokyo Women's Medical University, Tokyo, Japan.

    Papers in Europe PMC
  2. 02
    Argani P3 papers · 2017

    Department of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

    Papers in Europe PMC
  3. 03
    Ayala AG3 papers · 2018

    Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX 77030.

    Papers in Europe PMC
  4. 04
    Chen YB3 papers · 2019

    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

    Papers in Europe PMC
  5. 05
    Huang J3 papers · 2022

    Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

    Papers in Europe PMC
  6. 06
    Reuter VE3 papers · 2018
    Papers in Europe PMC
  7. 07
    Ro JY3 papers · 2018

    Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX 77030. Electronic address: jaero@houstonmethodist.org.

    Papers in Europe PMC
  8. 08
    Wang H3 papers · 2025

    Department of Pathology, The Third Affiliated Hospital of Soochow University 185 Juqian Street, Changzhou 213003, P. R. China.

    Papers in Europe PMC
  9. 09
    Wang L3 papers · 2022

    Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China.

    Papers in Europe PMC
  10. 10
    Zhang S3 papers · 2014
    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 48 trials are registered for renal carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

48 interventional trials matched renal carcinoma, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: renal carcinoma

48

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Mucinous tubular and spindle cell renal carcinoma" OR "carcinoma, renal, tubular, malignant" OR "mucinous tubular and spindle cell carcinoma of the kidney" OR "mucinous tubular and spindle cell carcinoma of kidney"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Mucinous tubular and spindle cell renal carcinoma" OR "carcinoma, renal, tubular, malignant" OR "mucinous tubular and spindle cell carcinoma of the kidney" OR "mucinous tubular and spindle cell carcinoma of kidney" OR "renal tubule disorder"

Recall-expansion terms: renal tubule disorder

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"renal carcinoma"

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T13:26:02.550Z